36. Emgality

Eli Lilly
(Eli Lilly)

Active ingredient: galcanezumab  
Disease: migraine  
Peak sales estimate: $700 million  
Approved: Sept. 27  
Company: Eli Lilly  

The scoop: With a late September approval, Eli Lilly’s Emgality was the third drug to join the CGRP inhibitor class to prevent migraines, following Amgen and Novartis’ Aimovig and Teva’s Ajovy. Despite its third-to-market launch, one Lilly exec told FiercePharma he believes the drug can be the “treatment of choice” in CGRP due to its efficacy, a 12-month free drug program by Lilly and Emgality’s ease of use. Emgality carries the same list price as its rivals. Along with Aimovig, the drug picked up an early coverage win from Express Scripts. And since its FDA approval to prevent migraines, Emgality has also secured an FDA “breakthrough” tag to prevent cluster headache. According to analysts cited by Bloomberg, the drug is expected to generate $700 million in 2022. — Eric Sagonowsky 

36. Emgality

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.